The fourth vaccine, "will not be a 4 / a dose but a booster, hopefully annual"
and "we will have to fraternize that too".
Thus Magrini, general manager of Aifa, to Elisir, on Rai Tre.
"The effectiveness of these vaccines - he said - went even better than expected, compared to the fact that they were discovered so quickly, that the study data was 95% effective and that it was confirmed in the 1st quarter. of real use. There was then a slow gradual loss of effectiveness even for a variant that partially reduced it ".
The scientific community, "has unanimously seen the extraordinary benefit everywhere".
"Novavax is coming, it should arrive on the 24th of this month and be available. It's a protein vaccine, like the flu vaccines. It will be a small supplement compared to the other mRna vaccines. Some who seem to prefer it, so Novavax will soon be an option. for a million or two of people who still want to get vaccinated, "said Magrini, commenting on the data from the vaccine report presented yesterday.
"While Valneva", she added, "is an even more classic vaccine and with an older technology, it is an inactivated vaccine that will come even further."
In any case, those with mRna "have proved to be the most effective vaccines" and "about which there is no doubt about genetic and genetic interference".